Hallucinations during voriconazole therapy: who is at higher risk and could benefit from therapeutic drug monitoring?
Pea
Federico
F
Viale
Pierluigi
P
D000935:Antifungal Agents / Q000009:adverse effects* / Q000493:pharmacokinetics*; D016903:Drug Monitoring; D006212:Hallucinations / Q000139:chemically induced* / Q000523:psychology*; D006801:Humans; D020258:Neurotoxicity Syndromes / Q000201:enzymology / Q000235:genetics / Q000523:psychology*; D011743:Pyrimidines / Q000009:adverse effects* / Q000493:pharmacokinetics*; D018570:Risk Assessment; D014230:Triazoles / Q000009:adverse effects* / Q000493:pharmacokinetics*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole